CAP Profiles

Bio

Clinical Focus

  • Neurology
  • Neuromuscular Diseases

Academic Appointments

Professional Education

  • Medical Education:SUNY Downstate School of Medicine Registrar (2007) NY
  • Board Certification: Electrodiagnostic Medicine, American Association of Neuromuscular (2013)
  • Fellowship:Stanford University Medical Center (2012) CA
  • Board Certification: Neurology, American Board of Psychiatry and Neurology (2011)
  • Residency:Stanford University Medical Center (2011) CA
  • Internship:Winthrop University Hospital (2008) NY

Contact

    • Tel: (650) 723-3677
    Fax: (650) 736-6603
  • Stanford Neuroscience Health Center 213 Quarry Rd Rm 2851 MC 5957 Palo Alto, CA 94304
    • Tel: (650) 723-5072
    Fax: (650) 725-7459
  • 211 Quarry Rd Ste 206 Hoover Bldg MC 5992 Palo Alto, CA 94304
    • Tel: (650) 498-7551
    Fax: (650) 725-4197

Research & Scholarship

Current Research and Scholarly Interests

Dr. Goyal specializes in the diagnosis, management, and electrophysiological testing of neuromuscular diseases. Through collaboration with a multidisciplinary team including therapists, research scientists, and ancillary staff, her work focuses on providing state of the art, comprehensive care to patients living with neuromuscular diseases. Her clinical research interests include ALS and sleep, hereditary neuropathies, and neuromuscular junction disorders.

Publications

All Publications

  • Making sense of antisense oligonucleotides: A narrative review MUSCLE & NERVE Goyal, N., Narayanaswami, P. 2018; 57 (3): 356–70

    Abstract

    Synthetic nucleic acid sequences that bind to ribonucleic acid (RNA) through Watson-Crick base pairing are known as antisense oligonucleotides (ASOs) because they are complementary to "sense strand" nucleic acids. ASOs bind to selected sequences of RNA and regulate the expression of genes by several mechanisms depending on their chemical properties and targets. They can be used to restore deficient protein expression, reduce the expression of a toxic protein, modify functional effects of proteins, or reduce toxicity of mutant proteins. Two ASOs were approved by the U.S. Food and Drug Administration in 2016: eteplirsen for Duchenne muscular dystrophy and nusinersen for spinal muscular atrophy. Clinical trials in amyotrophic lateral sclerosis and familial amyloid polyneuropathy are ongoing. We review the chemistry, pharmacology, and mechanisms of action of ASOs, preclinical data, and clinical trials in neuromuscular diseases and discuss some ethical, regulatory, and policy considerations in the clinical development and use of ASOs. Muscle Nerve 57: 356-370, 2018.

    View details for DOI 10.1002/mus.26001

    View details for Web of Science ID 000425107600009

    View details for PubMedID 29105153